Therapy with the histone deacetylase inhibitor pracinostat for patients with myelofibrosis
about
Evolving Therapeutic Strategies for the Classic Philadelphia-Negative Myeloproliferative NeoplasmsNovel therapies for myelofibrosisHistone deacetylase inhibitor pracinostat in doublet therapy: a unique strategy to improve therapeutic efficacy and to tackle herculean cancer chemoresistance.A phase I study of panobinostat (LBH589) in patients with primary myelofibrosis (PMF) and post-polycythaemia vera/essential thrombocythaemia myelofibrosis (post-PV/ET MF).Ruxolitinib: long-term management of patients with myelofibrosis and future directions in the treatment of myeloproliferative neoplasmsThe potential of panobinostat as a treatment option in patients with relapsed and refractory multiple myeloma.Histone deacetylase inhibitors in clinical studies as templates for new anticancer agents.Advances in myelofibrosis: a clinical case approach.Emerging therapies for the treatment of chronic Philadelphia chromosome-negative myeloproliferative neoplasm-associated myelofibrosis.Clinical end points for drug treatment trials in BCR-ABL1-negative classic myeloproliferative neoplasms: consensus statements from European LeukemiaNET (ELN) and Internation Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT)Allo-SCT for myelofibrosis: reversing the chronic phase in the JAK inhibitor era?Setting Appropriate Goals for the Next Generation of Clinical Trials in Myelofibrosis.Investigational histone deacetylase inhibitors (HDACi) in myeloproliferative neoplasms.Developmental Therapeutics in Myeloproliferative Neoplasms.Novel Therapies for Myelofibrosis.Pharmacotherapy of Myelofibrosis.
P2860
Q26766319-D0105BE4-B808-4528-A5EA-16C494829A40Q28081693-31E8A220-A5DD-4BC5-9EE6-76B7A8577B12Q30251920-FFF70FD8-B971-44AB-B653-04587AE92F1BQ33405372-82017EC0-693D-4CE1-AD86-5409280547C7Q33417217-7105C767-7790-418B-ABA0-9227C609EEFFQ34602263-332ED79E-F4E0-4538-B495-CA8DB84299F1Q35214924-B88C5C1B-312A-4DA7-83DF-C032B3240226Q37212674-9047CAA7-5161-42FE-A88E-82D22119EC5CQ38143243-A6FDFBE8-A9D3-471B-81D4-7ACEBCA0021BQ38242725-A82F45B2-F316-4F63-9E13-59F375608CCAQ38349213-E7F2D2FA-4106-4E3C-9D46-F79E65EBB930Q38567540-190EB59A-2AAA-46CE-82A2-55F14515FB98Q38984578-63EE56B2-2832-40F7-A0C8-30C3E01905A8Q48008083-3E2CE90E-24A0-4A4B-88DE-DE9DA61F3477Q52817185-5995AA12-FDB3-4E51-BF69-322FA5D9C092Q53119304-1C16BA68-6701-45DA-B148-CA34402A7C70
P2860
Therapy with the histone deacetylase inhibitor pracinostat for patients with myelofibrosis
description
2012 nî lūn-bûn
@nan
2012 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2012 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
name
Therapy with the histone deace ...... or patients with myelofibrosis
@ast
Therapy with the histone deace ...... or patients with myelofibrosis
@en
type
label
Therapy with the histone deace ...... or patients with myelofibrosis
@ast
Therapy with the histone deace ...... or patients with myelofibrosis
@en
prefLabel
Therapy with the histone deace ...... or patients with myelofibrosis
@ast
Therapy with the histone deace ...... or patients with myelofibrosis
@en
P2860
P50
P1433
P1476
Therapy with the histone deace ...... or patients with myelofibrosis
@en
P2093
Alfonso Quintás-Cardama
P2860
P304
P356
10.1016/J.LEUKRES.2012.03.003
P577
2012-04-02T00:00:00Z